Kadmon (KDMN) Stock Analysis

What Kadmon does

Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2), which is currently undergoing Phase II clinical evaluation for chronic graft-versus-host disease and various fibrotic conditions. Another key oral ROCK inhibitor, KD045, is also in development for fibrotic diseases. Additionally, the company is advancing KD033, an anti-PD-L1/IL-15 fusion protein, for oncological applications. Kadmon's broader pipeline encompasses Tesevatinib for autosomal dominant polycystic kidney disease; ribavirin, a nucleoside inhibitor, targeting hepatitis; and CLOVIQUE (trientine hydrochloride capsules) for the management of Wilson's disease. The company has established strategic partnerships and licensing agreements with entities like Nano Terra, Inc. and Dyax Corp. Established in 2010, Kadmon Holdings, Inc. maintains its headquarters in New York, New York.

Key metrics

ETFs linked to KDMN

Broad-market and Healthcare sector ETFs an investor holding Kadmon is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KDMN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kadmon?

Kadmon trades under the ticker KDMN on NYSE.

Which exchange is KDMN listed on?

KDMN is listed on NYSE.

What sector does Kadmon operate in?

Kadmon is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KDMN in a portfolio?

PortView shows KDMN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.